GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Winddown Corp (OTCPK:PLXPQ) » Definitions » Free Cash Flow

PLx Pharma Winddown (PLx Pharma Winddown) Free Cash Flow : $-59.34 Mil (TTM As of Sep. 2022)


View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Winddown Free Cash Flow?

PLx Pharma Winddown's total free cash flow for the months ended in Sep. 2022 was $-10.98 Mil. Its total free cash flow for the trailing twelve months (TTM) ended in Sep. 2022 was $-59.34 Mil.

PLx Pharma Winddown's Free Cash Flow per Share for the months ended in Sep. 2022 was $-0.38. Its free cash flow per share for the trailing twelve months (TTM) ended in Sep. 2022 was $-2.14.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Free Cash Flow Growth Rate using Free Cash Flow per Share data.


PLx Pharma Winddown Free Cash Flow Historical Data

The historical data trend for PLx Pharma Winddown's Free Cash Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma Winddown Free Cash Flow Chart

PLx Pharma Winddown Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Free Cash Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.85 -10.15 -12.90 -12.35 -32.12

PLx Pharma Winddown Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Free Cash Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.00 -13.36 -16.89 -18.10 -10.98

PLx Pharma Winddown Free Cash Flow Calculation

Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.

PLx Pharma Winddown's Free Cash Flow for the fiscal year that ended in Dec. 2021 is calculated as

Free Cash Flow (A: Dec. 2021 )=Cash Flow from Operations+Capital Expenditure
=-32.118+0
=-32.12

PLx Pharma Winddown's Free Cash Flow for the quarter that ended in Sep. 2022 is calculated as

Free Cash Flow (Q: Sep. 2022 )=Cash Flow from Operations+Capital Expenditure
=-10.982+0
=-10.98

Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-59.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PLx Pharma Winddown  (OTCPK:PLXPQ) Free Cash Flow Explanation

Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.

In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.

This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over seven years. The reason we use seven years is because research shows that seven years is the length of the typical business cycle.

Therefore, as of Sep22, PLx Pharma Winddown's Forward Rate of Return (Yacktman) % is

Forward Rate of Return (Yacktman) % (Sep22)=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0.65+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.


PLx Pharma Winddown Free Cash Flow Related Terms

Thank you for viewing the detailed overview of PLx Pharma Winddown's Free Cash Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


PLx Pharma Winddown (PLx Pharma Winddown) Business Description

Traded in Other Exchanges
N/A
Address
8 The Green, Suite 11895, Dover, DE, USA, 19901
PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.
Executives
Rita M O'connor officer: Chief Financial Officer 4 OAK PARKWAY, SPARTA NJ 07871
Natasha Giordano director, officer: Chief Executive Officer 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael J Valentino director, officer: Executive Chairman 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
John Hadden director 1375 S FORT HARRISON AVE, CLEARWATER FL 33756
Robert D. Hardie 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Molly G. Hardie 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Level One Partners, Llc 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Kirk K Calhoun director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Gary S. Balkema director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Robert Casale director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Anthony Bartsh director C/O PARK WEST ASSET MANAGEMENT, LLC, 900 LARKSPUR CIRCLE, SUITE 165, LARKSPUR CA 94939
Park West Asset Management Llc 10 percent owner 1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129
Efthymios Deliargyris officer: Chief Medical Officer C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Gary L Mossman officer: Chief Operating Officer 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
David Emerson Jorden officer: Acting Chief Financial Officer 2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381

PLx Pharma Winddown (PLx Pharma Winddown) Headlines

From GuruFocus

PLx Pharma Inc. Receives Nasdaq Delisting Notice

By sperokesalga sperokesalga 04-11-2023